دورية أكاديمية
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.
| العنوان: | Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study. |
|---|---|
| المؤلفون: | Ter Haar ELM; Department of Dermatology, Radboud University Medical Centre (Radboudumc), PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Elke.terHaar@radboudumc.nl.; Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands. Elke.terHaar@radboudumc.nl., Thomas SE; Department of Dermatology, Radboud University Medical Centre (Radboudumc), PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands., van den Reek JMPA; Department of Dermatology, Radboud University Medical Centre (Radboudumc), PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands., Otero ME; Department of Dermatology, Radboud University Medical Centre (Radboudumc), PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands., Njoo MD; Department of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands., Ossenkoppele PM; Department of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands., Kop EN; Department of Dermatology, Bernhoven Ziekenhuis, Uden, The Netherlands., Dodemont SRP; Department of Dermatology, Catharina Ziekenhuis, Eindhoven, The Netherlands., Körver JEM; Department of Dermatology, Amphia Ziekenhuis, Breda, The Netherlands., Kuijpers ALA; Department of Dermatology, Máxima Medisch Centrum, Eindhoven, The Netherlands., Lindhout RJ; Department of Dermatology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, The Netherlands., Tupker RA; Department of Dermatology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands., Mommers JM; Department of Dermatology, Anna Ziekenhuis, Geldrop, The Netherlands., Berends MAM; Department of Dermatology, Slingeland Ziekenhuis, Doetinchem, The Netherlands., Koetsier MIA; Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands., de Bruin-Weller MS; Department of Dermatology, Utrecht Medisch Centrum, Utrecht, The Netherlands., Visch MB; Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, The Netherlands., Arnold WP; Department of Dermatology, Ziekenhuis Gelderse Vallei, Ede, The Netherlands., van Lümig PPM; Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands., Kleinpenning MM; Department of Dermatology, Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands., Lubeek SFK; Department of Dermatology, Radboud University Medical Centre (Radboudumc), PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands., de Jong EMGJ; Department of Dermatology, Radboud University Medical Centre (Radboudumc), PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands.; Radboud University, Nijmegen, The Netherlands. |
| المصدر: | Drugs & aging [Drugs Aging] 2022 Sep; Vol. 39 (9), pp. 715-727. Date of Electronic Publication: 2022 Jul 21. |
| نوع المنشور: | Journal Article; Observational Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9102074 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1969 (Electronic) Linking ISSN: 1170229X NLM ISO Abbreviation: Drugs Aging Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Auckland : Adis, Springer International Original Publication: Mairangi Bay, Auckland, N.Z. : Adis International, c1991- |
| مواضيع طبية MeSH: | Biological Products*/therapeutic use , Psoriasis*/drug therapy, Aged ; Humans ; Prospective Studies ; Registries ; Treatment Outcome |
| مستخلص: | Background: Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials, limited data specifically on this growing population are available, e.g. regarding the safety and performance of biological treatment. Aims: We aimed to give insight into this specific population by comparing the drug survival and safety of biologics in older patients with that in younger patients. Methods: In this real-world observational study, data from 3 academic and 15 non-academic centers in The Netherlands were extracted from the prospective BioCAPTURE registry. Biologics included in this study were tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors. Patients were divided into two age groups: ≥ 65 years and < 65 years. The Charlson Comorbidity Index (CCI) was used to measure comorbid disease status, and all adverse events (AEs) that led to treatment discontinuation were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) classification. All AEs that led to treatment discontinuation were studied to check whether they could be classified as serious AEs (SAEs). Kaplan-Meier survival curves for overall 5-year drug survival and split according to reasons of discontinuation (ineffectiveness or AEs) were constructed. Cox regression models were used to correct for possible confounders and to investigate associations with drug survival in both age groups separately. Psoriasis Area and Severity Index (PASI) scores during the first 2 years of treatment and at the time of treatment discontinuation were assessed and compared between age groups. Results: A total of 890 patients were included, of whom 102 (11.4%) were aged ≥ 65 years. Body mass index, sex, and distribution of biologic classes (e.g. TNFα, IL12/23) were not significantly different between the two age groups. A significantly higher CCI score was found in older patients, indicative of more comorbidity (p < 0.001). The 5-year ineffectiveness-related drug survival was lower for older patients (44.5% vs. 60.5%; p = 0.006), and the 5-year overall (≥ 65 years: 32.4% vs. < 65 years: 42.1%; p = 0.144) and AE-related (≥ 65 years: 82.1% vs. < 65 years: 79.5%; p = 0.913) drug survival was comparable between age groups. Of all AEs (n = 155) that led to discontinuation, 16 (10.3%) were reported as SAEs but these only occurred in younger patients. After correcting for confounders, the same trends were observed in the drug survival outcomes. Linear regression analyses on PASI scores showed no statistical differences at 6, 12, 18, and 24 months of treatment between age groups. Conclusions: This study in a substantial, well-defined, prospective cohort provides further support that the use of biologics in older patients seems well-tolerated and effective. Biologic discontinuation due to AEs did not occur more frequently in older patients. Older patients discontinued biologic treatment more often due to ineffectiveness, although no clear difference in PASI scores was observed. More real-world studies on physician- and patient-related factors in older patients are warranted. (© 2022. The Author(s).) |
| References: | Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification, Management of P, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85. https://doi.org/10.1038/jid.2012.339 . (PMID: 10.1038/jid.2012.33923014338) Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12. https://doi.org/10.1111/jdv.13854 . (PMID: 10.1111/jdv.1385427573025) van Winden MEC, van der Schoot LS, van de L’Isle AM, van Vugt LJ, van den Reek J, van de Kerkhof PCM, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol. 2020;156(11):1229–39. https://doi.org/10.1001/jamadermatol.2020.2311 . (PMID: 10.1001/jamadermatol.2020.231132822455) Schaap MJ, van Winden MEC, Seyger MMB, de Jong EMGJ, Lubeek SFK. Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: a systematic review. J Am Acad Dermatol. 2020;83(2):412–24. https://doi.org/10.1016/j.jaad.2019.07.079 . (PMID: 10.1016/j.jaad.2019.07.07931369769) Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463–70. (PMID: 10.1001/archdermatol.2011.2768) Geale K, Henriksson M, Schmitt-Egenolf M. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. Br J Dermatol. 2016;174(3):579–87. https://doi.org/10.1111/bjd.14331 . (PMID: 10.1111/bjd.1433126616003) Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174–86. https://doi.org/10.1177/1203475419897578 . (PMID: 10.1177/120347541989757831950853) Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF Jr, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65(3):537–45. https://doi.org/10.1016/j.jaad.2010.05.014 . (PMID: 10.1016/j.jaad.2010.05.01421496950) Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-8 . (PMID: 10.1016/0021-9681(87)90171-83558716) Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288–94. https://doi.org/10.1016/j.jclinepi.2004.03.012 . (PMID: 10.1016/j.jclinepi.2004.03.01215617955) von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. https://doi.org/10.1371/journal.pmed.0040296 . (PMID: 10.1371/journal.pmed.0040296) European Medicines Agency. ICH E6 (R2) good clinical practice. European Medicines Agency; 2016 [cited 12 Jan 2022]. van Lümig PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol. 2013;68(1):57–63. https://doi.org/10.1016/j.jaad.2012.05.040 . (PMID: 10.1016/j.jaad.2012.05.04022846689) Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7. (PMID: 10.2340/00015555-1719) Balato N, Patruno C, Napolitano M, Patrì A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31(4):233–8. https://doi.org/10.1007/s40266-014-0156-6 . (PMID: 10.1007/s40266-014-0156-624554398) Phan C, Sigal ML, Esteve E, Reguiai Z, Barthelemy H, Beneton N, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78–82. https://doi.org/10.1111/jdv.12850 . (PMID: 10.1111/jdv.1285025389080) Bland JM, Altman DG. Survival probabilities (the Kaplan–Meier method). BMJ. 1998;317(7172):1572. https://doi.org/10.1136/bmj.317.7172.1572 . (PMID: 10.1136/bmj.317.7172.157298366631114388) Wakkee M, Hollestein LM, Nijsten T. Multivariable analysis. J Invest Dermatol. 2014;134(5):1–5. https://doi.org/10.1038/jid.2014.132 . (PMID: 10.1038/jid.2014.13224732339) van den Reek J, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. Drug survival studies in dermatology:principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5. https://doi.org/10.1038/jid.2015.171 . (PMID: 10.1038/jid.2015.17126066896) Osuna CG, García SR, Martín JC, Jiménez VG, López FV, Santos-Juanes J. Use of biological treatments in elderly patients with skin psoriasis in the real world. Life (Basel). 2021;11:12. https://doi.org/10.3390/life11121348 . (PMID: 10.3390/life11121348) van Winden MEC, Ter Haar ELM, Groenewoud JMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups. Br J Dermatol. 2021;184(4):759–62. https://doi.org/10.1111/bjd.19665 . (PMID: 10.1111/bjd.1966533152111) Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis—a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700–8. https://doi.org/10.1111/jdv.15324 . (PMID: 10.1111/jdv.1532430388318) Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of attitudes toward deprescribing in older medicare beneficiaries in the United States. JAMA Intern Med. 2018;178(12):1673–80. https://doi.org/10.1001/jamainternmed.2018.4720 . (PMID: 10.1001/jamainternmed.2018.4720303260046583614) Sattar S, Alibhai SM, Wildiers H, Puts MT. How to implement a geriatric assessment in your clinical practice. Oncologist. 2014;19(10):1056–68. https://doi.org/10.1634/theoncologist.2014-0180 . (PMID: 10.1634/theoncologist.2014-0180251874774200997) van Winden MEC, ter Haar ELM, Groenewoud HMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Disease and treatment characteristics in geriatric psoriasis: a patient survey comparing age groups. Acta Derm Venereol. 2020;100(14):adv00215. https://doi.org/10.2340/00015555-3569 . (PMID: 10.2340/00015555-356932556353) Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31. https://doi.org/10.1111/bjd.12039 . (PMID: 10.1111/bjd.1203922963128) Hambly R, Kelly A, Gilhooley E, Nic Dhonncha E, Murad A, Hughes R, et al. Medication adherence among patients with psoriasis on traditional systemic and biologics treatment. Br J Dermatol. 2018;178(1):e46–8. https://doi.org/10.1111/bjd.15856 . (PMID: 10.1111/bjd.1585628762482) Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22. https://doi.org/10.1177/2042098615615472 . (PMID: 10.1177/2042098615615472268349594716390) Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology (Basel, Switzerland). 2012;225(4):312–9. https://doi.org/10.1159/000345623 . (PMID: 10.1159/000345623) Migliore A, Bizzi E, Laganà B, Altomonte L, Zaccari G, Granata M, et al. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol. 2009;22(2):415–26. https://doi.org/10.1177/039463200902200218 . (PMID: 10.1177/03946320090220021819505394) Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135–44. https://doi.org/10.1007/s40266-018-0520-z . (PMID: 10.1007/s40266-018-0520-z294049665847154) Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017;77(5):845-54.e5. https://doi.org/10.1016/j.jaad.2017.07.013 . (PMID: 10.1016/j.jaad.2017.07.01328893407) Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448–56. https://doi.org/10.1016/j.jaad.2009.09.040 . (PMID: 10.1016/j.jaad.2009.09.04020605254) Chimenti MS, Esposito M, Giunta A, Bavetta M, Rinaldi M, Chimenti S, et al. Efficacy and safety of subcutaneous anti-TNF alpha, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: An observational long term study. Annals of the Rheumatic Disease Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR. 2012;71. Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101–11. https://doi.org/10.1016/j.jaad.2005.11.1088 . (PMID: 10.1016/j.jaad.2005.11.108816488320) Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse AC, et al. Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis. Acta Derm Venereol. 2020;100(18):adv00316. https://doi.org/10.2340/00015555-3678 . (PMID: 10.2340/00015555-367833111960) Megna M, Napolitano M, Balato N, Monfrecola G, Villani A, Ayala F, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41(5):564–6. https://doi.org/10.1111/ced.12850 . (PMID: 10.1111/ced.1285027028505) Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–7. https://doi.org/10.1111/ced.14979 . (PMID: 10.1111/ced.1497934642965) Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gomez-Garcia FJ, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29(5):858–64. https://doi.org/10.1111/jdv.12688 . (PMID: 10.1111/jdv.1268825185962) |
| المشرفين على المادة: | 0 (Biological Products) |
| تواريخ الأحداث: | Date Created: 20220721 Date Completed: 20220913 Latest Revision: 20221018 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9300332 |
| DOI: | 10.1007/s40266-022-00961-y |
| PMID: | 35859228 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1179-1969 |
|---|---|
| DOI: | 10.1007/s40266-022-00961-y |